Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-targeting Antibody in Pancreatic Ductal Adenocarcinoma

Delta-24-RGD (DNX-2401) is a conditional replication-competent oncolytic virus engineered to preferentially replicate in and lyse tumor cells with abnormality of p16/RB/E2F pathway. In a phase 1 clinical trial, Delta-24-RGD has shown favorable safety profile and promising clinical efficacy in brain...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Main Authors: Dai, Bingbing, Roife, David, Kang, Ya’an, Gumin, Joy, Rios Perez, Mayrim V., Li, Xinqun, Pratt, Michael, Brekken, Rolf A., Fueyo-Margareto, Juan, Lang, Frederick F., Fleming, Jason B.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5512885/
https://ncbi.nlm.nih.gov/pubmed/28138026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0526
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares